Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00371995
Other study ID # LEI PDE 06 03
Secondary ID
Status Completed
Phase Phase 2
First received September 5, 2006
Last updated June 21, 2011
Start date October 2007
Est. completion date February 2010

Study information

Verified date September 2008
Source Banaras Hindu University
Contact n/a
Is FDA regulated No
Health authority India: Ministry of Health
Study type Interventional

Clinical Trial Summary

Miltefosine and liposomal amphotericin B (AmBisome) are approved drugs for visceral leishmaniasis. In this study both drugs will be given in a sequential manner. AmBisome will be given on day 1, followed by Miltefosine for 14 days. Final Cure will be evaluated at six months.


Description:

Methodology Multicenter trial, eligible patients will be treated with Liposomal amphotericin B (5 mg/kg) on day 1 and then with miltefosine capsules for 14 days (days 2-15).

At two weeks after the end of treatment the initial cure (clinical and parasitological cure) and the clinical response will be determined. If initial cure is observed, a patient will be evaluated after a 6 months (after end of treatment) follow up period for final clinical cure.

Number of patients planned Total number of patients planned: 150 patients at both centers combined. 75 pediatric (2-11 years); 75 adult (12-65 years).

Lack of suitability for the trial:

- Post Kala-azar Dermal Leishmaniasis (PKDL)

- Concomitant treatment with other anti-leishmanial drugs

- Any condition which compromises ability to comply with the study procedures

Administrative reasons:

- Any condition or situation that compromises compliance with study procedures including follow-up visit Study medication, dose and mode of administration Liposomal amphotericin B administered intravenously as single dose on day 1, Dosage: 5 mg/kg.

Miltefosine administered orally (50 mg capsules) for 14 days (on days 2-15)

Dosage:

1. weighing ≥ 25 kg: 100 mg miltefosine daily as one capsule (50 mg) in the morning and one capsule in the evening, after meals for 14 days.

2. weighing < 25 kg: 50 mg miltefosine daily as one capsule (50 mg) in the morning, after meals for 14 days. Parameter for evaluation

- Final cure rate (initial parasite cure and clinical assessment at six month EOT)

- Initial parasitological cure rate (based on splenic aspirates or Bone marrow aspirate)

- Clinical response at end of treatment (clinical assessment)

- Adverse events

Statistical methods

- Calculation of cure rate with 95% and 90% lower confidence limit according to Clopper Pearson

- Calculation of overall incidence of adverse events


Recruitment information / eligibility

Status Completed
Enrollment 150
Est. completion date February 2010
Est. primary completion date August 2009
Accepts healthy volunteers No
Gender Both
Age group 2 Years to 65 Years
Eligibility Inclusion Criteria:

- Male and female age between 2 and 65 years (inclusive)

- Parasites visualized on splenic aspiration

- Signs and symptoms compatible with visceral leishmaniasis (e.g. fever, splenomegaly, anaemia, weight loss, leucopenia, thrombocytopenia)

- Confirmed diagnosis of VL by visualization of parasites on splenic/bone marrow aspirate

- Fever for at least 2 weeks

- Written informed consent from the patient/or from parent or guardian if under 18 years old

Exclusion Criteria:

- Hemoglobin < 6 g/dl

- White blood cell count < 1000/mm3

- Platelets <50,000

- Prothrombin time > 5 sec above control

- ASAT > 3 times the upper limit of normal

- Serum creatinine or BUN > 1.5 times the upper limit of normal

- Malaria

- Tuberculosis

- HIV positive serology

- Lactation, pregnancy

- Refusing contraception method during treatment period plus 3 months

- Any medical condition(s) that upon judgment of physician may affect the safety of the patient when treated with study drugs

- Any concomitant drug that is nephrotoxic

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Liposomal amphotericin B and Miltefosine
Liposomal amphotericin B administered intravenously as single dose on day 1, Dosage: 5 mg/kg. Miltefosine administered orally (50 mg capsules) for 14 days (on days 2-15)

Locations

Country Name City State
India Kala-azar Medical Research Center Muzaffarpur Bihar
India Rajendra Memorial Research Institute of Medical Sciences Patna Bihar

Sponsors (2)

Lead Sponsor Collaborator
Banaras Hindu University Rajendra Memorial Research Institute of Medical Sciences

Country where clinical trial is conducted

India, 

References & Publications (1)

Sundar S, Sinha PK, Verma DK, Kumar N, Alam S, Pandey K, Kumari P, Ravidas V, Chakravarty J, Verma N, Berman J, Ghalib H, Arana B. Ambisome plus miltefosine for Indian patients with kala-azar. Trans R Soc Trop Med Hyg. 2011 Feb;105(2):115-7. doi: 10.1016/ — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Final Cure six months after the end of treatment 1 year Yes
See also
  Status Clinical Trial Phase
Terminated NCT02839603 - Asymptomatic Leishmania Infection in HIV Patients
Completed NCT00370825 - Combination Chemotherapy for the Treatment of Indian Kala-Azar Phase 2
Recruiting NCT05426577 - Evaluation of Less Invasive Procedures for Visceral Leishmaniasis Treatment Efficacy Monitoring Test of Cure
Completed NCT01069198 - A Community Trial for Visceral Leishmaniasis (VL) N/A
Completed NCT01032187 - Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children Phase 4
Completed NCT00604955 - Expand Access/Assess Safety and Efficacy of Paromomycin IM Injection for the Treatment of Visceral Leishmaniasis Phase 4
Completed NCT00342823 - Immunogenetics of Visceral Leishmaniasis N/A
Completed NCT04003532 - LAMP Assay for the Diagnosis of Visceral Leishmaniasis
Terminated NCT01980199 - Trial to Determine Efficacy of Fexinidazole in Visceral Leihmaniasis Patients in Sudan Phase 2
Completed NCT00255567 - Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis Phase 3
Not yet recruiting NCT06118749 - Leishmania Antigen Rapid Diagnostic Test Proof-of-Concept and Validation Study
Recruiting NCT04342715 - A Study to Assess Immune Response Status in Patients Before and After Treatment for Visceral Leishmaniasis
Completed NCT02431143 - Pharmacokinetics/Safety of Miltefosine Allometric Dose for the Treatment of Visceral Leishmaniasis in Children in Eastern Africa Phase 2
Completed NCT01122771 - Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh Phase 3
Completed NCT03636659 - Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition Phase 1
Not yet recruiting NCT01566552 - Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis Phase 4
Completed NCT00696969 - Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis Phase 3
Completed NCT00318721 - Efficacy, Acceptability and Cost-effectiveness of Long Lasting Insecticide Nets (LLIN) in the Prevention of Kala Azar N/A
Completed NCT00216346 - Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis Phase 3
Completed NCT02011958 - Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients. Phase 3